| The effects of chronic betaine supplementation on body composition and performance in collegiate females: a double-blind, randomized, placebo controlled trial 2018 · Betaine · Women aged 18–35 who were physically active and resistance-training naïve, without stated disease | 1.25 g | 9 weeks | 11 |
| Betaine supplementation improves CrossFit performance and increases testosterone levels, but has no influence on Wingate power: randomized crossover trial 2023 · 2.5 g/d BET · Men aged 18–45 in good health with at least one year of CrossFit training and at least two CrossFit sessions per week | 2.5 g | 3 weeks | 24 |
| Betaine Supplementation Improves 60 km Cycling Time Trial Performance and One-Carbon Metabolism in Cyclists During Recovery 2025 · betaine · Healthy male and female cyclists aged 18–65, capable of cycling 60 km, without gastrointestinal or chronic disease | 3 g | 2 weeks | 23 |
| Effects of chronic betaine supplementation on performance in professional young soccer players during a competitive season: a double blind, randomized, placebo-controlled trial 2021 · betaine group · Male professional youth soccer players competing in the Iranian Youth Premier League; exact age range not stated | 2 g | 14 weeks | 15 |
| Betaine Supplementation Does Not Improve Muscle Hypertrophy or Strength Following 6 Weeks of Cross-Fit Training 2020 · Betaine supplementation (BET) · Men and women aged 18–40 years with BMI 18.5–24.9 kg/m² and at least 6 months of CrossFit experience | 2.5 g | 6 weeks | 14 |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 2 betaine 1.5 g group · Healthy adults aged 30–50 years with plasma total homocysteine below 25 μmol/L | 1.5 g | 6 weeks | 19 |
| S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse 2010 · Group B · Adults aged 18–65 with chronic hepatitis C and previous nonresponse to interferon/ribavirin combination treatment | 6 g | 48 weeks | 17 |
| S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse 2010 · Group A · Adults aged 18–65 with chronic hepatitis C and previous nonresponse to interferon/ribavirin combination treatment | 6 g | 49 weeks | 16 |
| Betaine supplementation improves CrossFit performance and increases testosterone levels, but has no influence on Wingate power: randomized crossover trial 2023 · 5.0 g/d BET · Men aged 18–45 in good health with at least one year of CrossFit training and at least two CrossFit sessions per week | 5 g | 3 weeks | 19 |
| Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects 2002 · betaine-supplemented group · Obese adults (14 men and 28 women) treated with a hypoenergetic diet; ages not reported | 6 g | 12 weeks | — |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 2 betaine 3 g group · Healthy adults aged 30–50 years with plasma total homocysteine below 25 μmol/L | 3 g | 6 weeks | 19 |
| The Impacts of Combined Blood Flow Restriction Training and Betaine Supplementation on One-Leg Press Muscular Endurance, Exercise-Associated Lactate Concentrations, Serum Metabolic Biomarkers, and Hypoxia-Inducible Factor-1α Gene Expression 2022 · BET (betaine) group · Recreationally resistance-trained men aged 18–35, described as apparently healthy | 6 g | 2 weeks | 9 |
| Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy 2000 · Folic acid 5 mg daily with betaine 4 g per day (12-week phase) · Adults on maintenance dialysis with end-stage renal disease and hyperhomocysteinemia | 4 g | 12 weeks | — |
| A study of the treatment of Rett syndrome with folate and betaine 2009 · Folate–betaine combination, participants weighing less than 30 kg · Females aged 1.2–28.9 years with Rett syndrome and a MECP2 gene mutation; participants in this dose subgroup weighed less than 30 kg | 6 g | 1 year | — |
| A study of the treatment of Rett syndrome with folate and betaine 2009 · Folate–betaine combination, participants weighing more than 30 kg · Females aged 1.2–28.9 years with Rett syndrome and a MECP2 gene mutation; participants in this dose subgroup weighed more than 30 kg | 12 g | 1 year | — |
| Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans 2006 · 1 g betaine · Healthy adults, 40.8 ± 12.4 years old, normal body weight | 1 g | 1 day | 10 |
| Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males 2009 · Betaine supplement · Healthy males aged 22–36 years | 1 g | 2 weeks | 8 |
| Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans 2006 · 3 g betaine · Healthy adults, 40.8 ± 12.4 years old, normal body weight | 3 g | 1 day | 10 |
| Effect of Folic Acid, Betaine, Vitamin B₆, and Vitamin B12 on Homocysteine and Dimethylglycine Levels in Middle-Aged Men Drinking White Wine 2016 · Betaine group · Healthy men aged 37–65 years who were moderate alcohol consumers | 3 g | 4 weeks | 25 |
| The effects of 14-week betaine supplementation on endocrine markers, body composition and anthropometrics in professional youth soccer players: a double blind, randomized, placebo-controlled trial 2021 · Betaine group (BG) · Male professional U16 youth soccer players competing in the Iranian Youth Premier League; ages 15.0–15.8 years | 2 g | 14 weeks | 14 |
| Effects of 14-weeks betaine supplementation on pro-inflammatory cytokines and hematology status in professional youth soccer players during a competition season: a double blind, randomized, placebo-controlled trial 2021 · Betaine group (BG) · Male professional youth soccer players, age 15–16, competing in the Iranian Youth Premier League | 2 g | 14 weeks | 14 |
| Betaine supplementation enhances anabolic endocrine and Akt signaling in response to acute bouts of exercise 2013 · Betaine (B) · Trained men, mean age 19.7 years | 2.5 g | 2 weeks | 12 |
| Creatine but not betaine supplementation increases muscle phosphorylcreatine content and strength performance 2012 · betaine (BET) · Untrained subjects; age and sex not specified | 2 g | 10 days | — |
| Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans 2006 · 6 g betaine · Healthy adults, 40.8 ± 12.4 years old, normal body weight | 6 g | 1 day | 10 |
| Consumption of wheat aleurone-rich foods increases fasting plasma betaine and modestly decreases fasting homocysteine and LDL-cholesterol in adults 2010 · Aleurone-rich cereal products · Healthy adults aged 45–65 years with BMI ≥25 kg/m² | 279 mg | 4 weeks | — |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 3 betaine group · Healthy adults aged 50–70 years with plasma total homocysteine below 26 μmol/L | 6 g | 6 weeks | 40 |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 2 betaine 6 g group · Healthy adults aged 30–50 years with plasma total homocysteine below 25 μmol/L | 6 g | 6 weeks | 19 |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 1 betaine group · Healthy adults aged 30–50 years with plasma total homocysteine below 25 μmol/L | 6 g | 6 weeks | 12 |
| Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial 2022 · Betaine 100 mg/kg/day · Children aged 1–18 years with pyridoxine-nonresponsive CBS deficiency or cblC deficiency | 100 mg/kg | 30 days | 11 |
| Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial 2022 · Betaine 250 mg/kg/day · Children aged 1–18 years with pyridoxine-nonresponsive CBS deficiency or cblC deficiency | 250 mg/kg | 30 days | 11 |
| High- but not low-dose folic acid improves endothelial function in coronary artery disease 2006 · Betaine group · Patients with coronary artery disease; age and sex not reported | 100 mg/kg | 6 weeks | — |
| Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes 2018 · betaine · People with obesity and prediabetes | 9.9 g | 12 weeks | — |
| Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure 2002 · Folic acid, pyridoxine, and glycine betaine · Patients with chronic renal failure who were folate and pyridoxine replete | 4 g | 90 days | 36 |
| Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients 1999 · Folic acid 5 mg daily with betaine · Adults with end-stage renal disease receiving maintenance haemodialysis | 4 g | 12 weeks | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 5 mg folic acid plus 4 g betaine (phase 1) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 4 g | 12 weeks | — |
| Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy 1998 · 5 mg folic acid and 4 g betaine daily · Peritoneal dialysis patients with hyperhomocysteinemia | 4 g | 12 weeks | — |
| Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial 2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia | 2 g | 90 days | 105 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · drink powder · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 4 g | 12 weeks | 93 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 250 mg | 60 days | 52 |
| Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial 2023 · supplement group · Chinese adults aged 18–65 with hyperhomocysteinemia (blood homocysteine 15–100 μmol/L) | 1 g | 12 weeks | 44 |